Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results by Argüelles Arias, Federico et al.
Switching from reference inﬂiximab to CT-P13 in
patients with inﬂammatory bowel disease: 12 months
results
Federico Argüelles-Ariasa, Maria Fernanda Guerra Veloza, Raul Perea Amarilloa, Angel Vilches-Arenasb,
Luisa Castro Lariaa, Belen Maldonado Péreza, Dina Chaaro Benallala, Antonio Benítez Roldána, Vicente Merinoc,
Gabriel Ramirezc, Miguel Angel Calleja-Hernándezc, Angel Caunedo Álvareza and Manuel Romero Gómezd
Background Biological agents, such as inﬂiximab, have transformed the outcomes of patients with immune-mediated
inﬂammatory diseases. The advent of biosimilar treatment options such as CT-P13 promises to improve the availability of
biological therapy, yet real-world switching data are currently limited. Here, we assess the effectiveness and safety of switching to
CT-P13 from inﬂiximab reference product (RP) in patients with inﬂammatory bowel disease.
Materials and methods This was a prospective single-center observational study in patients with moderate to severe Crohn’s
disease (CD) and ulcerative colitis (UC). All patients were switched from inﬂiximab RP (Remicade) to CT-P13 treatment and
followed up for up to 12 months. The efﬁcacy endpoint was the change in clinical response assessed at 3-monthly intervals,
according to the Harvey–Bradshaw score and partial Mayo score for patients with CD and UC, respectively. C-reactive protein
(CRP) was also measured. Adverse events were monitored and recorded throughout the study.
Results A total of 98 patients with inﬂammatory bowel disease (67 CD/31 UC) were included. A total of 83.6% (56/67) of
patients with CD were in remission at the time of the switch and 62.7% were in remission at 12 months. The Harvey–Bradshaw
score showed a signiﬁcant change at 12 months (P=0.007) but no signiﬁcant change was observed in median CRP at this
timepoint (P= 0.364). A total of 80.6% (25/31) of patients with UC were in remission at the time of the switch and 65.3% (18/28)
were in remission at 12 months. No signiﬁcant changes in the median partial Mayo score (P=0.058) or CRP (P=0.329) were
observed at 12 months. Serious adverse events related to medication were reported in 11 (11.2%) patients.
Conclusion Switching from inﬂiximab RP to CT-P13 is efﬁcacious and well tolerated in patients with CD or UC for up to
12 months. Eur J Gastroenterol Hepatol 29:1290–1295
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc.
Introduction
Over the past 20 years, the introduction of biological
agents into clinical practice has radically improved out-
comes in patients with immune-mediated inﬂammatory
diseases. This includes the two major types of inﬂamma-
tory bowel disease (IBD): Crohn’s disease (CD) and
ulcerative colitis (UC) [1]. Tumor necrosis factor-α (TNF-
α) antagonists, such as inﬂiximab, act by preventing TNF-
α from binding to its receptor, neutralizing its activity and
alleviating mucosal inﬂammation [2]. In Europe, the anti-
TNF-α agents authorized by the European Medicines Agency
(EMA) for use in IBD are inﬂiximab [3], adalimumab [4],
and golimumab [5]. However, biological agents are much
more expensive than traditional treatments, and the high cost
of these drugs in the treatment of IBD imposes a considerable
burden on the national healthcare system [6]. As a result,
interest in biosimilars has grown as biosimilar agents are
highly similar in terms of quality, efﬁcacy, and safety to
already licensed biologics [7] but are associated with lower
development costs. Thus, biosimilars may be available at a
lower price and have the potential to offer considerable cost
savings to healthcare systems [8].
CT-P13 (Remsima and Inﬂectra) is a biosimilar of inﬂix-
imab (Remicade), which is its reference product (RP). Both
CT-P13 and inﬂiximab RP are chimeric immunoglobulin G1
monoclonal antibodies produced in cell lines derived from
the same cell type of murine hybridoma. These monoclonal
antibodies have an identical amino acid sequence and highly
comparable higher-order structures [9].
CT-P13 was authorized by the EMA in 2013 for several
indications, including IBD [10], based on two pivotal
clinical trials in patients with rheumatoid arthritis (RA) and
ankylosing spondylitis. The efﬁcacy and pharmacokinetic
equivalence of CT-P13 and inﬂiximab RP were demon-
strated in these two randomized trials at 30 weeks, and
safety proﬁles were comparable for both inﬂiximab
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formulations [11,12]. Results up to week 54 demonstrated
continued comparability between CT-P13 and its RP in
both patient populations [13,14]. Furthermore, in exten-
sions of these studies, similar efﬁcacy and safety proﬁles
were observed in patients with RA and ankylosing spon-
dylitis who switched from RP to CT-P13 for an additional
year compared with those who continued CT-P13 treat-
ment for 2 years [15,16]. In patients with IBD, a number of
observational studies of CT-P13 in clinical practice in both
anti-TNF-α-naive patients [17–22] and those who have
been switched from inﬂiximab RP [23,24] have been pub-
lished with good results. Furthermore, results from the
randomized, phase IV, double-blind, parallel-group NOR-
SWITCH study (NCT02148640) have recently been
reported [25] and other similar randomized controlled
trials have been initiated in patients with IBD [26,27] but
are either ongoing or awaiting results. On the basis of the
current regulatory guidance from the EMA, and the evi-
dence for efﬁcacy and safety of biosimilars in patients with
IBD, the European Crohn’s Colitis Organisation has
recently published its position statement on the use of
biosimilars for IBD [28] and states that ‘when a biosimilar
product is registered in the European Union, it is con-
sidered to be as efﬁcacious as the reference product when
used in accordance with the information provided in the
Summary of Product Characteristics’. The consensus
statement supports switching between an originator and
biosimilar product, but notes the lack of data regarding
reverse switching, multiple switching, and cross-switching
among biosimilars in IBD patients, and further explains
that demonstration of the safety of biosimilars requires
large observational studies with long-term follow-up in this
patient group.
Until data from randomized controlled trials in CD and
UC are available, results from ‘real-world’ clinical use of the
biosimilar can offer valuable insights into its efﬁcacy and
safety. Here, we describe an observational study assessing
the efﬁcacy and safety of switching from inﬂiximab RP to
CT-P13 in patients with IBD for up to 12 months.
Materials and methods
Study design
This was a prospective observational study conducted at the
VirgenMacarena Hospital (Seville, Spain) fromMarch 2015
to February 2016. The study was approved by the Research
Ethics Committee of the Virgen Macarena Hospital. Good
clinical practice guidelines were followed and written
informed consent was obtained from all patients.
Patients
Patients with moderate to severe CD or UC who had
previously been treated with and had responded to inﬂix-
imab RP were included in the study. Montreal classiﬁca-
tion status was recorded in all patients before enrollment.
All patients were switched from inﬂiximab RP (Remicade;
Janssen Biologics B.V., Leiden, The Netherlands) to CT-
P13 (Remsima; Celltrion, Incheon, South Korea) and
treated according to the dosage and regime recommended
by the Summary of Product Characteristics of Remsima
in Spain [29]. All patients received intravenous
corticosteroids and antihistamines as premedication before
the infusion treatment.
Study endpoints and assessments
The efﬁcacy endpoint was the change in clinical remission
in patients switched from inﬂiximab RP assessed at
12 months, according to the Harvey–Bradshaw (HB) score
for patients with CD and the partial Mayo score for
patients with UC.
The HB and partial Mayo scores were assessed by the
treating physician in consultations held every 3 months.
Changes in C-reactive protein (CRP), and in the HB and
partial Mayo scores, were reported in all patients in
remission at 12 months.
In patients with CD and UC who were in remission at
the time of the switch, remission was considered to be
maintained if the patient remained in clinical remission
(HB score ≤ 4 in patients with CD or partial Mayo score
≤ 2 in patients with UC) after switching without the need
for steroids, surgery, or increased dosage. In patients with
CD and UC who were not in remission at the time of the
switch, remission was considered to be achieved when a
HB score less than or equal to 4 (in patients with CD) or a
partial Mayo score less than or equal to 2 (in patients with
UC) was reached. The HB and partial Mayo scores in
patients with CD and UC, respectively, and CRP in all
patients were compared from month 0 to month 12.
Adverse events (AE) were monitored from the ﬁrst
infusion of CT-P13 until the end of the study and were
recorded according to the Ofﬁce of Human Research
Protection [30].
Statistical analysis
Demographic and nominal results were reported in per-
centages and frequencies. Numerical results were reported
as average and SD in cases of normal distribution and as
median and interquartile range (IQR) in cases of skewed
distribution. The Cochrane’s Q test and the Friedman test
were used to analyze the evolution of the clinical scores
(HB score and partial Mayo score) and CRP values of
patients. The 95% conﬁdence intervals (95% CIs) were
calculated and α was set at 0.05 for the determination of
statistical signiﬁcance. Analyses were performed using
SPSS 23 (IBM Corporation, Armonk, New York, USA).
Results
Patients
A total of 98 patients with IBD (67 with CD and 31 with
UC) were included in this study. The median (range) age of
patients with CD was 42 (38–44) years and for patients
with UC was 43 (38–48) years. Over half of the patient
population (56.1%; n=55) were men and 68.3% (n= 67)
were nonsmokers. In all, 56.7% with CD and 38.7% with
UC used concomitant thiopurines. The baseline demo-
graphics and phenotypic characteristics of patients with
CD and UC according to the Montreal classiﬁcation and
prior medication exposure are shown in Table 1.
In the CD patient group, median (IQR) duration of
ongoing inﬂiximab RP treatment at the start of the study
was 297 (158–432) weeks. Patient withdrawals from this
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group were as follows: at 3 months post switch, one patient
was withdrawn because of an AE; at 6 months, two had
discontinued treatment (one patient because of an AE; one
patient required surgery); at 9 months, one patient was
withdrawn because of an AE; and at 12 months, a further
two patients did not continue treatment (one patient because
of an AE, and one patient did not attend follow-up visits).
In the UC patient group, median (IQR) duration of
ongoing inﬂiximab RP treatment at the start of the study
was 203 (42–294) weeks. At 6 months post switch, three
patients stopped treatment: two because of clinical and
endoscopic remission and one because of a lack of
response to treatment. At 12 months post switch, another
three patients discontinued treatment: one because of a
lack of response to treatment, one because of maintained
remission with mucosa healing, and one because of an AE.
Efﬁcacy
Crohn’s disease patient group
At the start of this study, 83.6% (56/67) of patients with
CD were in remission. After patients were switched from
inﬂiximab RP to CT-P13, 79.1% (53/67), 76.1% (51/67),
71.6% (48/67), and 62.7% (42/67) of CD patients were in
remission at 3, 6, 9, and 12 months, respectively (Fig. 1).
In total, 91.0% (61/67) of patients with CD completed
12 months of follow-up.
In total, 56 patients were in remission at the time of
switch. Of the patients in remission at months 3, 6, 9 and
12, respectively, 87.5% (49/56), 83.9% (47/56), 76.4%
(42/55), and 69.8% (37/53) had remained in remission
since switching, with statistically signiﬁcant differences
observed over this period (P= 0.034). Of the 11 patients
who were not in remission at the time of switch, 4, 5, 4,
and 5 patients reached remission at 3, 6, 9, and 12 months,
respectively, post switch.
The HB score showed signiﬁcant changes over the
12-month period [median HB score (95% CI): 1 (1–2); 1
(1–3); 1 (1–3); 2 (1–2); 1 (1–3) at months 0, 3, 6, 9, and 12,
respectively; P<0.001]. The difference was observed between
months 0 and 9 (P=0.010), and months 0 and 12
(P=0.007). No signiﬁcant changes in median (95% CI) CRP
levels were observed in patients with CD over the same period
[1 (0–6); 1 (0–6.3); 2 (0–6.5); 1 (0.1–3.7); 0.36 (0.2–2) at 0, 3,
6, 9, and 12 months, respectively; P=0.364] (Fig. 2).
Ulcerative colitis patient group
At the start of the study, 80.6% (25/31) of patients with
UC were in remission. After patients were switched from
inﬂiximab RP to CT-P13, 77.4% (24/31), 75.9% (22/29),
69.0% (20/29), and 64.3% (18/28) of patients were in
remission at 3, 6, 9, and 12 months, respectively (Fig. 3).
In total, 80.6% (25/31) of patients with UC completed
12 months of follow-up.
Overall, 25 patients with UC were in remission at the
time of the switch. Of the patients in remission at 3, 6, 9, and
12 months, respectively, 92.0% (23/25), 91.3% (21/23),
82.6% (19/23), and 81.0% (17/21) had maintained remis-
sion since switching, without statistically signiﬁcant differ-
ences (P=0.700). Of the six patients with UC who were not
Table 1. Baseline characteristics in study patients
Characteristics n=98 [n (%)] 95% CI
Sex
Men 55/98 (56.1) 45.8–66.5
Women 43/98 (43.9) 33.5–54.2
Age, median (range), years
Crohn’s disease 42 (38–44)
Ulcerative colitis 43 (38–48)
Smoking status
Never 67/98 (68.3) 58.7–78.1
Previous 18/98 (18.4) 10.2–26.5
Current 13/98 (13.3) 6.0–20.5
CD patients
Age at diagnosis
A1 (<16 years) 7/ 67 (10.4) 2.4–18.5
A2 (16–40 years) 49/67 (73.1) 61.8–84.5
A3 (>41 years) 11/67 (16.4) 6.8–26.0
Location at diagnosis
L1 (ileal) 18/67 (26.9) 15.5–38.2
L2 (colonic) 26/67 (38.8) 26.4–51.2
L3 (ileocolonic) 21/67 (31.3) 19.5–43.2
L4 (upper gastrointestinal tract) 2/67 (3) 0.3–10.4
Disease behavior
B1 (nonstricturing, nonpenetrating) 38/67 (56.7) 44.1–69.3
B2 (stricturing) 14/67 (20.9) 10.4–31.4
B3 (penetrating) 15/67 (22.4) 11.7–33.1
Perianal disease
Proportion of patients with perianal disease 37/67 (55.2) 42.6–67.9
Extraintestinal manifestations
Proportion of patients with no extraintestinal
manifestations
42/67 (62.7) 50.4–75.0
UC patients
Extent (UC)
E1 (proctitis) 13/31 (41.9) 22.9–60.9
E2 (left sided colitis) 10/31 (32.3) 14.2–50.3
E3 (pancolitis) 8/31 (25.8) 8.8–42.9
Severity
S1 (mild) 11/31 (35.5) 17–53.9
S2 (moderate) 16/31 (51.6) 32.4 –70.8
S3 (severe) 4/31 (12.9) 3.6–29.8
Extraintestinal manifestations
Proportion of patients with no extraintestinal
manifestations
26/31 (83.9) 66.3–94.5
Prior medication exposure
Thiopurines
CD 48/67 (71.6) 60.1–83.2
UC 27/31 (87.1) 70.2–96.4
Methotrexate
CD 20/67 (29.9) 18.1–41.5
UC 5/31 (16.1) 5.4–33.7
Concomitant medications use
5-aminosalicylic acid
CD 20/67 (29.9) 18.1–41.5
UC 22/31 (70.9) 53.4–88.6
Thiopurines
CD 38/67 (56.7) 44.1–69.3
UC 12/31 (38.7) 19.9–57.5
Methotrexate
CD 10/67 (14.9) 5.6–24.2
UC 3/31 (9.7) 2.0–25.7
CD, Crohn’s disease; CI, conﬁdence interval; UC, ulcerative colitis.
Fig. 1. Global remission in patients with Crohn’s disease.
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in remission at the time of the switch, only one patient
reached remission at 3, 6, 9, and 12 months.
No signiﬁcant changes in the median (95% CI) partial
Mayo score were observed in switched patients over the
12 months [2 (1–3); 1 (1–3); 1 (0–9); 1 (0–4); 1 (0–3) at 0,
3, 6, 9, and 12 months, respectively; P=0.058]. No sig-
niﬁcant changes in the median CRP level (95% CI) were
observed over the same period [2 (1–10); 1 (0–2); 1 (0–5);
1 (0–2); 0.5 (0.2–1.4) at months 0, 3, 6, 9, and 12,
respectively; P= 0.329] (Fig. 4).
Safety
In total, 11 AEs occurred in 11/98 (11.2%) patients: one
skin reaction, one case of abdominal pain, two cases of
headache and two of paresthesia during infusion, one case
of Sweet’s syndrome, two of polyarthralgia, and two of
palpitations. Six patients discontinued treatment because
of AEs. Two AEs were considered to be serious: one
patient with CD who had Sweet’s syndrome needed hos-
pitalization and discontinued treatment. In addition, one
patient with UC discontinued because of paresthesia
during the infusion.
Discussion
Until data from randomized controlled trials of CT-P13 in
CD and UC are available, results from its use in clinical
practice can provide valuable information relating to the
efﬁcacy and tolerability of the biosimilar in these indica-
tions. Here we report results from the ﬁrst prospective
observational study that analyzes the response of switch-
ing to CT-P13 from inﬂiximab RP in patients with IBD at
12 months. Results indicate that CT-P13 treatment is
effective and safe for up to 1 year in patients switched from
inﬂiximab RP. At 12 months, remission was maintained in
69.8% (37/53) of patients with CD and 81.0% (17/21) of
patients with UC. Thus, disease worsening occurred in
30.2 and 19.0% of patients with CD and UC who were in
remission at study commencement, respectively. Among
CD patients, HB score was signiﬁcantly altered between
baseline and months 9 and 12, yet despite these changes
the median overall score did not fall outside the classiﬁ-
cation of remission (< 5). No signiﬁcant changes in median
partial Mayo score were observed in UC patients and CRP
levels remained unchanged in both groups.
As is well known, monoclonal antibodies that target
TNF-α are effective for the induction and maintenance of
remission in IBD [31]. However, many patients who
initially respond to these treatments later experience a loss
of efﬁcacy, coinciding with a ﬂare of symptoms. A review
by Gisbert and Panes [32] found that 37% of patients with
CD lost their response to inﬂiximab and calculated the
annual risk for this loss to be 13% per patient per year
[32]. In the ACT I and II trials, ∼45% of patients with UC
had a sustained response to inﬂiximab at week 54,
meaning that 55% of patients lost their response during
the year [33,34]. Similarly, in a retrospective study, 59%
of patients with UC demonstrated a secondary loss of
response during maintenance treatment with inﬂiximab, at
a mean time of 59 weeks [35]. The results of the current
study support these previous ﬁndings.
In our study, patients were switched from inﬂiximab RP
to CT-P13 and the clinical response monitored for
12 months. Unfortunately, few similar studies exist with
Fig. 2. Evolution of Harvey–Bradshaw score and C-reactive protein from 0 to 12 months. CRP, C-reactive protein.
Fig. 3. Global remission in patients with ulcerative colitis.
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which to compare our results. The NOR-SWITCH trial
did include patients with IBD who were switched from
inﬂiximab RP to CT-P13 [27], in addition to patients with
RA, spondyloarthritis, psoriatic arthritis, and chronic
plaque psoriasis. For all indications, disease worsening
occurred in 26.2% in the inﬂiximab RP arm and 29.6% in
the CT-P13 arm. The worsening rate in patients with CD
was 36.5% and in patients with UC it was 11.9%. Our
results could be considered better in the case of CD
(30.2%) and worse for UC (19.0%). However, the NOR-
SWITCH trial was not powered to assess changes within
each indication, so these results must be interpreted with
caution. In addition, in our study we considered that a
patient was in remission at switching if he were on stable
inﬂiximab RP treatment at that time, applying generic and
disease-speciﬁc outcome measures, whereas in the NOR-
SWITCH study the patient must have been on stable
inﬂiximab RP treatment for at least 6 months to be eligible
for participation. In the PROSIT-BIO study, 97 patients
with CD switched to CT-P13 after a mean of 18 ±14
infusions of inﬂiximab RP. After 8, 16, and 24 weeks 94.5,
90.8, and 78.9% maintained efﬁcacy of treatment [36].
All observational postmarketing studies published to
date have reported positive outcomes for efﬁcacy measures
in patients with CD and UC treated with CT-P13, irre-
spective of prior anti-TNF-α treatment [17–24]. Jung et al.
[17] studied a total of 110 patients with IBD treated with
CT-P13, which included 36 patients who were switched
from inﬂiximab RP. In these patients, 92.6% (25/27) of
patients with CD and 66.7% (6/9) of patients with UC
maintained a similar efﬁcacy compared with previous
inﬂiximab treatment. Smits et al. [23] studied a cohort of
83 Remicade-treated patients with IBD who were switched
to CT-P13. They found that disease activity remained
stable after switching and that over 80% of patients
maintained clinical remission.
In the current study, AEs occurred in 11 of the 98
(11.2%) patients with IBD. To date, no unexpected
treatment-emergent adverse events (TEAEs) have been
observed in patients with CD and UC treated with CT-P13
[17–25]. A Korean study in 95 patients with CD and 78
patients with UC treated with CT-P13 reported that
treatment-related TEAEs occurred in 10% of patients.
Most of these were mild to moderate in severity; however,
ﬁve serious TEAEs were also reported [19].
Our study has some limitations. First of all, and perhaps
most importantly, as an observational study of the long-
term efﬁcacy and safety of switching from inﬂiximab RP to
CT-P13 in patients with IBD, our study demonstrates the
long-term outcomes of these patients, but does not enable
us to comment on the comparative efﬁcacy compared with
patients who did not switch. Similarly, we could not
measure drug trough levels or the presence of antidrug
antibodies as has been done in other studies. Therefore, it
has not been possible to ascertain the cause of the loss of
response observed in some patients. We were also unable
to measure mucosal healing or fecal calprotectin as a
biomarker of relapse in patients with IBD.
In conclusion, this study provides valuable data on the
long-term efﬁcacy of CT-P13 maintenance treatment after
switching from inﬂiximab RP, and demonstrates effec-
tiveness and safety at 12 months.
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